A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms TRANSCEND-NHL-006
- Sponsors Juno Therapeutics
- 29 Jan 2019 Planned End Date changed from 2 May 2021 to 30 Dec 2021.
- 29 Jan 2019 Planned primary completion date changed from 2 May 2021 to 30 Dec 2021.
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.